Pre-filled syringe systems are increasingly considered for injectable therapies that require accurate dosing, simplified preparation, and convenient self-administration. However, selecting a suitable delivery device involves more than placing a pre-filled syringe inside an outer housing. Pharmaceutical companies must evaluate the syringe format, dose volume, drug characteristics, activation method, injection process, and intended users as one integrated system.
A PFS auto-injector pen combines a pre-filled syringe with an automatic injection mechanism. It is generally designed as a ready-to-use, single-dose device that can reduce the manual steps associated with a conventional syringe. For GLP-1 therapies and biologics, this format can provide a practical route from a filled syringe to a patient-oriented delivery system.
PFS stands for pre-filled syringe. In a PFS auto-injector, the syringe already contains the required medication and is installed within an automated device. Instead of manually controlling the plunger, the user activates the mechanism and the device performs the injection sequence.
The exact operation depends on the design. A platform may use button or push-on-skin activation and may include a concealed needle, dose-completion feedback, and a needle shield. These elements can simplify the injection sequence and reduce direct handling of the syringe.
Compared with a traditional syringe, a PFS auto-injector can eliminate steps such as drawing medication from a vial and manually measuring the dose. For pharmaceutical companies, however, the device and syringe must be evaluated together. Syringe dimensions, fill volume, plunger movement, and delivery force can all influence the final configuration.
A typical sequence begins with removing the cap and placing the device against the injection site. Once activated, the device initiates the injection and delivers the pre-measured dose. Depending on the design, visual, audible, or tactile feedback may indicate that delivery has started or finished.
The number of user steps is particularly important for self-administration. A simpler sequence may reduce hesitation and handling errors, but the team must still evaluate grip, activation force, viewing windows, instructions for use, and dose-completion confirmation.
Wanhai Medical's WH-DF is a disposable auto-injector for pre-filled glass or polymer syringes. It uses push-on-skin activation, and the usage procedure shown on the product page consists of removing the cap and injecting.
Syringe size is one of the first technical decisions in a PFS auto-injector project. A 1 mL format may suit lower-volume injections and support a more compact device. A 2.25 mL syringe provides greater capacity but may require a different structure, drive system, and delivery profile.
The choice should not be based on volume alone. Pharmaceutical teams should also assess formulation viscosity, required injection time, plunger force, and the intended injection experience. A larger fill volume or more viscous formulation may require greater force or longer delivery time, affecting the device configuration and how long the user holds it against the skin.
The WH-DF specification lists a 1 mL format with a dose range of 0.15 to 1.00 mL and a 2.25 mL format with a dose range of 0.50 to 2.00 mL for selected applications. These ranges are a starting point; compatibility must still be confirmed for the specific syringe and formulation.
GLP-1 projects can involve different dosing schedules, volumes, and delivery formats. A company may consider a conventional disposable pen injector, reusable pen, multi-dose auto-injector, or single-dose PFS device depending on the formulation and commercial strategy.
Wanhai Medical lists Tirzepatide and Semaglutide among the applications associated with WH-DF. Its wider GLP-1 portfolio also presents device options for Semaglutide, Tirzepatide, Liraglutide, Mazdutide, and Enoglimab. This shows why selection should begin with the specific drug project rather than assuming one injector format suits every therapy.
For a PFS-based GLP-1 project, the team should review fill volume, dosing frequency, activation method, dose-confirmation approach, and whether a single-dose device matches the intended product presentation. The device should be assessed as part of the complete drug, syringe, and delivery-system combination.
Biologic formulations can create different device requirements because dose volume and formulation properties vary. Wanhai Medical lists applications including Adalimumab, Alirocumab, Ixekizumab, Secukinumab, Omalizumab, Sarilumab, Fremanezumab, and Dupilumab for WH-DF.
When evaluating an auto-injector for a biologic, the development team should consider syringe material, fill volume, injection force, delivery time, and needle protection. The intended users also matter. Some may have limited hand strength or dexterity, making grip, activation, and feedback especially important.
The objective is not simply to automate an injection, but to create a system in which the syringe, mechanism, and user interface work consistently together. Device evaluation should therefore consider both technical compatibility and the practical injection experience.
The process should begin with a clear device requirement profile covering the drug type, syringe size, syringe material, dose volume, formulation viscosity, intended users, target markets, and annual demand.
Pharmaceutical companies should then ask potential auto-injector pen manufacturers several practical questions:
Which pre-filled syringe sizes and materials can the platform support?
What dose ranges are available?
How are injection force and delivery time evaluated?
Which activation and dose-confirmation options are available?
Can samples be provided for compatibility evaluation?
What customization, tooling, and production support can be offered?
How will the project move from design and testing to mass production?
Manufacturing capability should also be reviewed early. Wanhai Medical presents an integrated process covering design, tooling, injection molding, QC inspection, screen printing, assembly, and final quality control. Its manufacturing facilities include Class 100,000 cleanroom molding and assembly areas, automated production, and inline inspection.
A PFS auto-injector pen can provide a ready-to-use delivery format for GLP-1 drugs and biologics, but successful selection depends on the complete system. Syringe size, fill volume, formulation properties, activation method, delivery time, user feedback, and manufacturing requirements must be considered together. Comparing 1 mL and 2.25 mL formats is therefore only one part of the broader device-development decision.
Wanhai Medical supports pharmaceutical and biopharmaceutical projects with PFS auto-injector pen platforms, including the WH-DF Disposable Auto-Injector Pen for pre-filled syringe applications. Its capabilities cover design, tooling, injection molding, assembly, and quality control, helping project teams evaluate a suitable device direction and prepare for scalable production.
Contact Wanhai Medical to discuss your PFS auto-injector project!
Hey, I'm Mike, a R&D engineer at Wanhai Medical, and I work with injection pens every day.
In the past decade, we have provided products and integrated services to over 180 renowned pharmaceutical companies, serving clients across more than 60 countries and territories worldwide.
My days are a "battle for details". This job's meaning is in countless "gentle moments". It turns cold medical processes into warm help, easing long-term injectors' fear and boosting their confidence. Behind it all is my social responsibility, rooted in professionalism and passion: "to make sure every user is well cared for."
中文
English
français
Español
العربية
русский
